Galderma, CH1335392721

Galderma stock gets Mexico approval for first global jawline use

Published on 11/17/2026 at 11:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Galderma stock is in focus after Mexico approved Restylane Shaype for chin and jawline use. The company expects a first-half 2027 launch.

Mexico approval expands Restylane reach

  • Mexico approved Restylane Shaype for temporary chin augmentation and improved jawline definition.
  • The decision marks the product's first approval worldwide for a jawline indication.
  • Galderma anticipates launching the product in Mexico during the first half of 2027.
Galderma, CH1335392721, Illustration mit AI erstellt.

Mexico approved Galderma's Restylane Shaype for temporary chin augmentation and improved jawline definition on November 13, according to a report carried by AFP that reproduced the company's release. The decision gives the product its first approval worldwide for a jawline indication and expands its use in Mexico beyond the chin.

Galderma said the product is already approved for chin augmentation in several markets, including Europe, Brazil, Canada and Thailand. The company anticipates a Mexican launch in the first half of 2027, putting the commercial rollout after the regulatory milestone rather than alongside it.

Approval opens a new aesthetic indication

Restylane Shaype is a hyaluronic acid injectable developed for structural enhancement of the lower face. Galderma describes the gel as a firmer formulation designed to create a bone-mimicking effect while maintaining a natural appearance without surgery.

The company linked the approval to demand for treatments addressing facial balance and definition. Its cited chin study found improved structure and definition for 83% of participants after three months and 66% after 12 months. In jawline research, improvements were maintained for up to two years, while 70% of participants reported better overall satisfaction with their appearance.

Launch timing remains the next milestone

For Galderma, the approval broadens the addressable use of an existing aesthetic product and adds a new geography for a jawline indication. The revenue contribution will depend on the timing of the launch, local adoption by physicians and patients, and the pace at which the product is incorporated into treatment practices.

Galderma's global head of research and development, Baldo Scassellati Sforzolini, said the approval strengthens the Restylane portfolio and reflects the company's focus on science-based treatments for changing patient needs. The company also highlighted its Shayping Technique, which combines facial assessment methods with treatment planning for the chin and jawline.

Galderma stock traded at 206.00 euros on Lang & Schwarz at 11:36 CET on Tuesday, November 17.

Galderma Group AG

  • ISIN: CH1335392721
  • Ticker: GALD.SW
  • Primary listing: SIX Swiss Exchange
  • Lang & Schwarz quote: 206.00 euros at 11:36 CET on Tuesday, November 17, 2026
  • Approval: Restylane Shaype for chin and jawline use in Mexico
  • Expected launch: First half of 2027

European aesthetic-treatment demand and healthcare shares remain the broader market context for the company. See current SMI market coverage for the Swiss benchmark.

For ongoing company coverage, see More news and analyses on Galderma stock and Current market reports.

Disclaimer...
en | CH1335392721 | GALDERMA | boerse | 70526126 | bgmi